# Pathos AI

> Pathos AI is an AI-driven biotech company building what it describes as one of the largest multimodal foundation models in oncology. By combining millions of clinical, molecular, and imaging records with proprietary AI, Pathos aims to identify the right patients for a given therapy, design smarter adaptive clinical trials, and de-risk cancer drug development. Founded in 2020 by Eric Lefkofsky and Ryan Fukushima and led since 2025 by CEO Iker Huerga, the company raised a $365 million Series D that valued it at roughly $1.6 billion.

- **Founded:** 2020
- **Headquarters:** Chicago, Illinois, United States
- **Founders:** Eric Lefkofsky (Co-founder & Chairman), Ryan Fukushima (Co-founder)
- **Team size:** ~110 employees
- **Products:** Oncology Foundation Model, AI-Enabled Clinical Trial Platform, Clinical-Stage Pipeline
- **Notable:** Raised a $365 million Series D in May 2025, reaching a valuation of roughly $1.6 billion., Assembled a strategic syndicate that includes AstraZeneca and Tempus AI., Building what it describes as one of the largest multimodal foundation models in oncology.

## Products & services

- **Oncology Foundation Model** — A large multimodal foundation model for oncology that integrates deep clinical, molecular, and imaging data to power clinical asset selection, trial design, biomarker discovery, and therapeutic innovation.
- **AI-Enabled Clinical Trial Platform** — Uses patient data and AI to identify which patients will most benefit from a treatment, enabling adaptive trial design and faster go/no-go decisions run by small, AI-enabled teams.
- **Clinical-Stage Pipeline** — A pipeline of oncology drug candidates that Pathos develops and in-licenses, selecting and advancing assets using its data platform.

## Achievements

- Raised a $365 million Series D in May 2025, reaching a valuation of roughly $1.6 billion.
- Assembled a strategic syndicate that includes AstraZeneca and Tempus AI.
- Building what it describes as one of the largest multimodal foundation models in oncology.
- Recruited Iker Huerga - a cancer survivor and former AstraZeneca oncology chief data scientist and Tempus EVP - as CEO.
- Acquired oncology drug assets to expand its clinical-stage pipeline.

## Latest updates

- **2025-05** — Closed $365 million Series D financing at a valuation of roughly $1.6 billion to advance its oncology drug development platform.
- **2025-05** — Appointed Iker Huerga as Chief Executive Officer to lead the next era of AI-enabled drug development.
- **2025-04** — Launched a $400 million funding round, raising $283 million in equity as part of a broader strategic syndicate with AstraZeneca and Tempus.

## Links

- Website: https://pathos.com
- LinkedIn: http://www.linkedin.com/company/pathos-ai

---

Profile page: https://yespress.io/pathos
Published by YesPress — https://yespress.io
Last updated: 2026-07-18